SynthesisFrontiers in medicine2026
The benefit and risk of adding PD-1/PD-L1 inhibitors plus anti-VEGF drugs to transarterial chemoembolisation for unresectable, non-metastatic hepatocellular carcinoma: a pooled analysis of four RCTs.
Synthesis in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Transarterial chemoembolisation (TACE) is the standard treatment for unresectable, non-metastatic hepatocellular carcinoma (UR/NM HCC). The addition of PD-1/PD-L1 inhibitors (PIs) plus anti-VEGF drugs (AVDs) after TACE (TPA group) has been proposed as a strategy to enhance antitumor efficacy; however, evidence regarding its survival benefit is still uncertain. To address this issue, we performed a pooled analysis of randomized controlled trials (RCTs) to determine whether this combination strategy confers additional clinical benefit over TACE alone. Methods: Six databases were systematically searched to identify eligible RCTs comparing TPA with TACE alone among individuals diagnosed with UR/NM HCC. Key endpoints consisted of overall survival (OS) and progression-free survival (PFS), whereas additional endpoints covered tumor responses, adverse events (AEs), and patient status at the data cutoff. PFS and tumor responses were assessed according to both RECIST version 1.1 and mRECIST criteria. Results: A total of 4 RCTs (CARES-005, EMERALD-1, LEAP-012, and TALENTACE) involving 1,431 patients were included. Compared with TACE alone, TPA significantly improved PFS (HR: 0.62 [0.47, 0.81], Conclusion: In patients with UR/NM HCC, TPA significantly improves PFS and ORR but does not yet demonstrate a significant OS benefit, and it is associated with increased grade 3-4 AEs. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261290301, CRD420261290301.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.